Aspiriant LLC Buys New Holdings in Arcellx, Inc. $ACLX

Aspiriant LLC purchased a new position in shares of Arcellx, Inc. (NASDAQ:ACLX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 7,910 shares of the company’s stock, valued at approximately $516,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. CWM LLC increased its holdings in shares of Arcellx by 267.0% during the 3rd quarter. CWM LLC now owns 345 shares of the company’s stock worth $28,000 after acquiring an additional 251 shares during the last quarter. Integrated Wealth Concepts LLC boosted its position in Arcellx by 9.0% during the third quarter. Integrated Wealth Concepts LLC now owns 3,423 shares of the company’s stock worth $281,000 after purchasing an additional 283 shares during the period. MAI Capital Management acquired a new position in shares of Arcellx in the third quarter valued at $26,000. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Arcellx by 11.0% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 3,805 shares of the company’s stock valued at $312,000 after purchasing an additional 377 shares during the last quarter. Finally, State of Wyoming bought a new position in shares of Arcellx in the second quarter valued at about $28,000. Institutional investors own 96.03% of the company’s stock.

Insider Activity at Arcellx

In other Arcellx news, insider Rami Elghandour sold 89,916 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $113.92, for a total value of $10,243,230.72. Following the sale, the insider owned 276,051 shares of the company’s stock, valued at approximately $31,447,729.92. This trade represents a 24.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Christopher Heery sold 5,882 shares of the business’s stock in a transaction on Wednesday, January 14th. The stock was sold at an average price of $68.51, for a total value of $402,975.82. Following the transaction, the insider directly owned 23,749 shares of the company’s stock, valued at $1,627,043.99. This trade represents a 19.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 109,366 shares of company stock worth $11,526,708 in the last quarter. 8.35% of the stock is currently owned by company insiders.

Arcellx Stock Performance

NASDAQ:ACLX opened at $114.77 on Friday. The company has a market cap of $6.71 billion, a price-to-earnings ratio of -28.20 and a beta of 0.25. Arcellx, Inc. has a fifty-two week low of $47.86 and a fifty-two week high of $114.94. The stock has a fifty day moving average price of $95.96 and a 200-day moving average price of $83.67.

Arcellx (NASDAQ:ACLX) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.01) EPS for the quarter, hitting analysts’ consensus estimates of ($1.01). The company had revenue of $1.65 million for the quarter, compared to analysts’ expectations of $13.40 million. Arcellx had a negative return on equity of 55.42% and a negative net margin of 1,027.26%. Research analysts predict that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Leerink Partners restated a “market perform” rating and set a $115.00 price objective on shares of Arcellx in a research report on Tuesday, February 24th. Truist Financial raised Arcellx from a “hold” rating to a “strong-buy” rating in a research report on Friday, March 20th. Canaccord Genuity Group set a $115.00 price target on Arcellx in a report on Monday, February 23rd. Evercore set a $115.00 price target on Arcellx in a research note on Monday, February 23rd. Finally, Wells Fargo & Company lowered Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 price objective on the stock. in a report on Monday, February 23rd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, sixteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $111.87.

Arcellx Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.